For decades, Medicare has been legally prohibited from covering weight-loss medications—a statutory relic of an era when obesity was framed as a lifestyle choice rather than a chronic clinical condition. The Trump administration’s proposed BALANCE pilot program seeks to bypass this restriction, testing the hypothesis that broad access to GLP-1 drugs could improve health outcomes and potentially lower long-term costs for the federal government.
The initiative relies on a negotiated deal with pharmaceutical giants Eli Lilly and Novo Nordisk. Under the terms, the manufacturers would sell their popular obesity treatments to Medicare and Medicaid for $245 a month, with seniors’ out-of-pocket costs capped at $50. It is a significant price reduction aimed at proving the fiscal and medical viability of integrating metabolic health into the standard of care for the elderly.
However, the program’s momentum has slowed as private health insurers signal deep skepticism. Participation in the BALANCE pilot is voluntary, and many payers fear that even with discounted drug prices, the sheer volume of demand could create a "financial drain" on their operations. Without the cooperation of these insurers, the administration’s effort to modernize Medicare’s pharmacy benefit may remain a theoretical exercise.
With reporting from STAT News.
Source · STAT News (Biotech)
